Zoetis Inc. A Stock
Zoetis Inc. A Stock
Pros and Cons of Zoetis Inc. A in the next few years
Pros
Cons
Performance of Zoetis Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. A | -3.550% | -0.971% | -1.360% | -49.167% | -39.195% | -62.558% | -61.166% |
| AbbVie Inc. | 0.000% | 2.411% | -0.276% | 26.519% | 10.285% | 55.715% | 123.645% |
| Biogen Inc. | -0.280% | -2.268% | 1.226% | 60.181% | 17.905% | -29.328% | -38.833% |
| Elanco Animal Health Inc. | -4.180% | -11.234% | -9.315% | 33.842% | 2.013% | 76.975% | -20.728% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.
Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.
EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.
Comments
News
Zoetis Q2 Earnings Call Highlights
Key Points
- Interested in Zoetis Inc.? Here are five stocks we like better.
- Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while
Elanco Animal Health Q2 Earnings Call Highlights
Key Points
- Interested in Elanco Animal Health Incorporated? Here are five stocks we like better.
- Strong Q2 performance: Elanco reported revenue of $1.368 billion, up 10% year over year, while
Elanco Animal Health Q1 Earnings Call Highlights
Elanco Animal Health (NYSE:ELAN) raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based